Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SLDB NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSLDBSolid Biosciences$6.62+1.8%$7.47$2.72▼$8.87$651.74M2.471.18 million shs967,909 shsSRPTSarepta Therapeutics$16.80-0.9%$19.99$10.41▼$43.92$1.77B0.262.98 million shs1.96 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSLDBSolid Biosciences0.00%-4.34%-19.46%+15.94%+145.19%SRPTSarepta Therapeutics0.00%-4.27%-17.73%-11.02%-58.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSLDBSolid Biosciences$6.62+1.8%$7.47$2.72▼$8.87$651.74M2.471.18 million shs967,909 shsSRPTSarepta Therapeutics$16.80-0.9%$19.99$10.41▼$43.92$1.77B0.262.98 million shs1.96 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSLDBSolid Biosciences0.00%-4.34%-19.46%+15.94%+145.19%SRPTSarepta Therapeutics0.00%-4.27%-17.73%-11.02%-58.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSLDBSolid Biosciences 2.92Moderate Buy$16.36147.18% UpsideSRPTSarepta Therapeutics 2.11Hold$27.1761.75% UpsideCurrent Analyst Ratings BreakdownLatest SLDB and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026SLDBSolid Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$17.00 ➝ $18.005/13/2026SLDBSolid Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.005/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/27/2026SLDBSolid Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/21/2026SLDBSolid Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell4/7/2026SRPTSarepta Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$18.00 ➝ $19.003/26/2026SRPTSarepta Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $35.003/26/2026SRPTSarepta Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$12.00 ➝ $14.003/26/2026SRPTSarepta Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$9.00 ➝ $13.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSLDBSolid BiosciencesN/AN/AN/AN/A$3.80 per shareN/ASRPTSarepta Therapeutics$2.20B0.81N/AN/A$14.26 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSLDBSolid Biosciences-$174.32M-$1.95N/AN/AN/AN/A-73.42%-61.13%8/11/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A7.340.19-2.94%7.56%2.94%8/5/2026 (Estimated)Latest SLDB and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLDBSolid Biosciences-$0.40-$0.52-$0.12-$0.52N/AN/A5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million3/19/2026Q4 2025SLDBSolid Biosciences-$0.51-$0.50+$0.01-$0.53N/AN/A2/25/2026Q4 2025SRPTSarepta Therapeutics-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthSLDBSolid BiosciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSLDBSolid BiosciencesN/A13.1013.10SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSLDBSolid Biosciences81.46%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipSLDBSolid Biosciences1.90%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSLDBSolid Biosciences10098.45 million96.58 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSLDB and SRPT HeadlinesRecent News About These CompaniesKROS Stock Guide to Rinvatercept in DMD and ALS for 2026May 22 at 2:06 PM | finance.yahoo.comShould You Buy KROS After Q1 Miss and Takeda Deal Reset?May 22 at 2:06 PM | finance.yahoo.comKROS Turns to Next Wave of TGF-Beta Muscle TherapiesMay 22 at 2:06 PM | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20, 2026 | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20, 2026 | insidermonkey.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)May 17, 2026 | theglobeandmail.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.comSarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target UnchangedMay 15, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY)May 14, 2026 | theglobeandmail.comSarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Built On Soft FoundationsMay 14, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | businesswire.comSarepta Therapeutics (SRPT) Gets a Buy from OppenheimerMay 12, 2026 | theglobeandmail.comWells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)May 11, 2026 | theglobeandmail.comA Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline ProgressMay 9, 2026 | finance.yahoo.comVanguard Group Inc. Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPTMay 9, 2026 | marketbeat.comSarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush SaysMay 8, 2026 | finance.yahoo.comSarepta (SRPT) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comSRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growthMay 8, 2026 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 11.8% - Should You Sell?May 7, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLDB and SRPT Company DescriptionsSolid Biosciences NASDAQ:SLDB$6.62 +0.12 (+1.85%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.63 +0.01 (+0.15%) As of 05/22/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$16.80 -0.16 (-0.94%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$16.89 +0.09 (+0.51%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
